GroundRules
Browse US Code
Read the original sections, or search by topic.
- 21 U.S.C. § 335a · Debarment, temporary denial of approval, and suspension
- 21 U.S.C. § 335b · Civil penalties
- 21 U.S.C. § 335c · Authority to withdraw approval of abbreviated drug applications
- 21 U.S.C. § 336 · Report of minor violations
- 21 U.S.C. § 337 · Proceedings in name of United States; provision as to subpoenas
- 21 U.S.C. § 337a · Extraterritorial jurisdiction
- 21 U.S.C. § 341 · Definitions and standards for food
- 21 U.S.C. § 342 · Adulterated food
- 21 U.S.C. § 343 · Misbranded food
- 21 U.S.C. § 343–1 · National uniform nutrition labeling
- 21 U.S.C. § 343–2 · Dietary supplement labeling exemptions
- 21 U.S.C. § 343–3 · Disclosure
- 21 U.S.C. § 343a · Repealed. Pub. L. 106–554, § 1(a)(1) [title V, § 517], Dec. 21, 2000, 114 Stat. 2763, 2763A–73
- 21 U.S.C. § 344 · Emergency permit control
- 21 U.S.C. § 345 · Regulations making exemptions
- 21 U.S.C. § 346 · Tolerances for poisonous or deleterious substances in food; regulations
- 21 U.S.C. § 346a · Tolerances and exemptions for pesticide chemical residues
- 21 U.S.C. § 346b · Authorization of appropriations
- 21 U.S.C. § 347 · Intrastate sales of colored oleomargarine
- 21 U.S.C. § 347a · Congressional declaration of policy regarding oleomargarine sales
- 21 U.S.C. § 347b · Contravention of State laws
- 21 U.S.C. § 348 · Food additives
- 21 U.S.C. § 349 · Bottled drinking water standards; publication in Federal Register
- 21 U.S.C. § 350 · Vitamins and minerals
- 21 U.S.C. § 350a · Infant formulas
- 21 U.S.C. § 350a–1 · Protecting infants and improving formula supply
- 21 U.S.C. § 350b · New dietary ingredients
- 21 U.S.C. § 350c · Maintenance and inspection of records
- 21 U.S.C. § 350d · Registration of food facilities
- 21 U.S.C. § 350e · Sanitary transportation practices
- 21 U.S.C. § 350f · Reportable food registry
- 21 U.S.C. § 350g · Hazard analysis and risk-based preventive controls
- 21 U.S.C. § 350h · Standards for produce safety
- 21 U.S.C. § 350i · Protection against intentional adulteration
- 21 U.S.C. § 350j · Targeting of inspection resources for domestic facilities, foreign facilities, and ports of entry; annual report
- 21 U.S.C. § 350k · Laboratory accreditation for analyses of foods
- 21 U.S.C. § 350l · Mandatory recall authority
- 21 U.S.C. § 350l–1 · Annual report to Congress
- 21 U.S.C. § 350m · Requirements for critical food
- 21 U.S.C. § 351 · Adulterated drugs and devices
- 21 U.S.C. § 352 · Misbranded drugs and devices
- 21 U.S.C. § 353 · Exemptions and consideration for certain drugs, devices, and biological products
- 21 U.S.C. § 353a · Pharmacy compounding
- 21 U.S.C. § 353a–1 · Enhanced communication
- 21 U.S.C. § 353b · Outsourcing facilities
- 21 U.S.C. § 353c · Prereview of television advertisements
- 21 U.S.C. § 353d · Process to update labeling for certain generic drugs
- 21 U.S.C. § 354 · Veterinary feed directive drugs
- 21 U.S.C. § 355 · New drugs
- 21 U.S.C. § 355–1 · Risk evaluation and mitigation strategies
- 21 U.S.C. § 355–2 · Actions for delays of generic drugs and biosimilar biological products
- 21 U.S.C. § 355a · Pediatric studies of drugs
- 21 U.S.C. § 355b · Adverse-event reporting
- 21 U.S.C. § 355c · Research into pediatric uses for drugs and biological products
- 21 U.S.C. § 355c–1 · Report
- 21 U.S.C. § 355d · Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
- 21 U.S.C. § 355e · Pharmaceutical security
- 21 U.S.C. § 355f · Extension of exclusivity period for new qualified infectious disease products
- 21 U.S.C. § 355g · Utilizing real world evidence
- 21 U.S.C. § 355h · Regulation of certain nonprescription drugs that are marketed without an approved drug application
- 21 U.S.C. § 356 · Expedited approval of drugs for serious or life-threatening diseases or conditions
- 21 U.S.C. § 356–1 · Accelerated approval of priority countermeasures
- 21 U.S.C. § 356–2 · Accelerated approval Council
- 21 U.S.C. § 356a · Manufacturing changes
- 21 U.S.C. § 356b · Reports of postmarketing studies
- 21 U.S.C. § 356c · Discontinuance or interruption in the production of life-saving drugs
- 21 U.S.C. § 356c–1 · Annual reporting on drug shortages
- 21 U.S.C. § 356d · Coordination; task force and strategic plan
- 21 U.S.C. § 356e · Drug shortage list
- 21 U.S.C. § 356f · Hospital repackaging of drugs in shortage
- 21 U.S.C. § 356g · Standards for regenerative medicine and regenerative advanced therapies
- 21 U.S.C. § 356h · Competitive generic therapies
- 21 U.S.C. § 356i · Prompt reports of marketing status
- 21 U.S.C. § 356j · Discontinuance or interruption in the production of medical devices
- 21 U.S.C. § 356k · Platform technologies
- 21 U.S.C. § 356l · Advanced manufacturing technologies designation program
- 21 U.S.C. § 357 · Qualification of drug development tools
- 21 U.S.C. § 358 · Authority to designate official names
- 21 U.S.C. § 359 · Nonapplicability of subchapter to cosmetics
- 21 U.S.C. § 360 · Registration of producers of drugs or devices
- 21 U.S.C. § 360a · Clinical trial guidance for antibiotic drugs
- 21 U.S.C. § 360a–1 · Clinical trials
- 21 U.S.C. § 360a–2 · Susceptibility test interpretive criteria for microorganisms
- 21 U.S.C. § 360b · New animal drugs
- 21 U.S.C. § 360b–1 · Priority zoonotic animal drugs
- 21 U.S.C. § 360c · Classification of devices intended for human use
- 21 U.S.C. § 360c–1 · Reporting
- 21 U.S.C. § 360d · Performance standards
- 21 U.S.C. § 360e · Premarket approval
- 21 U.S.C. § 360e–1 · Pediatric uses of devices
- 21 U.S.C. § 360e–3 · Breakthrough devices
- 21 U.S.C. § 360e–4 · Predetermined change control plans for devices
- 21 U.S.C. § 360f · Banned devices
- 21 U.S.C. § 360g · Judicial review
- 21 U.S.C. § 360g–1 · Agency documentation and review of significant decisions regarding devices
- 21 U.S.C. § 360g–2 · Third party data transparency
- 21 U.S.C. § 360h · Notification and other remedies
- 21 U.S.C. § 360h–1 · Program to improve the device recall system
- 21 U.S.C. § 360i · Records and reports on devices
- 21 U.S.C. § 360j · General provisions respecting control of devices intended for human use